Alteogen's Novartis Deal Is Korea's Bet on Drug-Delivery Tech

The Deal

Alteogen, a South Korean biotech company that has spent the better part of a decade trying to prove it can do more than manufacture generic versions of blockbuster drugs, signed a deal with Novartis on October 2 that could make it one of the more interesting players in the global biosimilar ecosystem.

The agreement gives Novartis exclusive option rights to use Alteogen’s ALT-B4 technology to convert multiple biologic drugs from intravenous to subcutaneous formulations. If all options are exercised and every development and commercialization milestone is hit, Alteogen stands to receive up to $3.223 billion — roughly 4.4 trillion won — plus ongoing royalties on net sales.

That headline number is large, but the real story is what it represents: a Korean company licensing a proprietary delivery platform to one of the world’s biggest pharmaceutical firms, not the other way around.

What ALT-B4 Actually Does

ALT-B4, the generic name for which is berahyaluronidase alfa, is a recombinant human hyaluronidase built on Alteogen’s Hybrozyme platform. Hyaluronidase enzymes break down hyaluronic acid, a key structural component of the extracellular matrix that acts as a kind of biological glue between cells.

When injected alongside a biologic drug, ALT-B4 temporarily loosens that matrix, allowing the drug to spread and absorb through subcutaneous tissue far more efficiently than it normally would. The practical effect is that proteins and antibodies that patients currently receive through hours-long IV infusions at infusion centers can be delivered as a quick shot under the skin.

The difference isn’t just convenience. It’s capacity. Oncology drugs like Keytruda require specialized infusion infrastructure — nurses, chairs, monitoring equipment, sometimes days of patient time. Subcutaneous administration collapses all of that into minutes. That matters enormously in markets where infusion capacity is a bottleneck and patient burden is a real clinical and economic concern.

Why Novartis Matters Here

Novartis isn’t a company known for taking outsized risks on unproven delivery platforms. The fact that it signed a multi-option agreement with a South Korean biotech that had only one approved product in the market — the Keytruda SC formulation — suggests the data package Alteogen presented was compelling enough to override normal risk aversion.

CEO Jeon Tae-yeon noted that Novartis conducted evaluations of ALT-B4 across multiple modalities before committing. That language is worth sitting with: Novartis wasn’t looking at a single drug. It was evaluating a platform capable of transforming a portfolio of its own biologic products.

For a company like Novartis, which faces patent cliffs across several key products in the coming decade, a reliable subcutaneous conversion platform is strategically valuable. Each IV-to-SC switch can extend a drug’s market life, improve patient adherence, and reduce healthcare system costs. The economics favor the innovator.

This Already Worked Once

The Keytruda subcutaneous formulation approved by the US FDA in September 2024 and the European commissioning in November 2024 is not a theoretical exercise. Merck Sharp & Dohme (MSD) used ALT-B4 to convert Keytruda from its original IV schedule to subcutaneous administration, and the regulatory approvals cleared the path for commercial use.

That track record should matter. Regulatory agencies have already reviewed the safety and immunogenicity profile of ALT-B4 in a major oncology indication. Novartis is essentially buying into a platform with demonstrated credibility, not a lab curiosity.

Alteogen’s Four-Deal Quarter

This is Alteogen’s fourth ALT-B4 licensing deal this year, joining agreements with MSD, GSK, AstraZeneca, Daiichi Sankyo, Sandoz, and Intas. The list reads like a who’s who of the global generic and specialty pharma industry.

What’s notable is the pattern. These aren’t small regional deals. They’re partnerships with multinationals that have the distribution networks, regulatory expertise, and commercial scale to bring ALT-B4–based products to hundreds of millions of patients. Alteogen is positioning itself as the intermediary between biologic innovators and the delivery technology that could extend their commercial lives.

Korea’s Bio Play Is Shifting

South Korea’s biotech sector has long been defined by its biosimilar manufacturing engine. Companies like Samsung Biologics and Celltrion built global reputations producing high-quality biosimilars at competitive cost. But manufacturing is a service business with thin margins and intense competition from Chinese and Indian players who can undercut on price.

Licensing a proprietary platform technology is a different game entirely. It moves a company up the value chain from contract manufacturer to technology exporter. Alteogen’s approach — build a delivery platform, prove it works, license it to the biggest pharma companies — mirrors the strategy Japan’s Daiichi Sankyo has pursued with ADC technology, or the way Chinese company WuXi AppTec became indispensable through platform capabilities rather than commodity manufacturing alone.

The Alt-B4 deals suggest South Korea is beginning to export drug-delivery intellectual property, not just filled vials. That distinction matters for margins, for geopolitical positioning, and for how the global supply chain views Korean biotech.

Who Wins, Who Loses

Alteogen wins the most immediate upside. The milestone payments and royalties from Novartis, combined with the existing pipeline of deals, could transform the company’s revenue profile within a few years. The risk is execution — converting platform options into actual approved products across multiple partners requires coordinated clinical development, regulatory navigation, and manufacturing at scale.

Novartis wins access to a proven platform without building it in-house. The company avoids the years of R&D spend and clinical risk that would come with developing its own hyaluronidase technology. In exchange, it surrenders some leverage and commits to royalty payments that will accumulate as products launch.

Patients win if the deal accelerates subcutaneous availability of oncology drugs that are currently IV-only. Shorter administration times, fewer clinic visits, and potentially lower healthcare system costs are the tangible benefits.

The losers are the companies that bet on developing competing delivery platforms. Alteogen has first-mover advantage in hyaluronidase-mediated subcutaneous biologics with a growing portfolio of approved and in-development indications. Other platform developers will need to demonstrate superior efficacy or safety to displace ALT-B4 in an already crowded market.

What Comes Next

The Novartis deal alone won’t determine Alteogen’s trajectory. The company still needs to execute on the development milestones for each option Novartis activates. Any stumble in clinical trials or regulatory filings could compress the deal’s value.

But the broader signal is clear: South Korea’s biotech sector is no longer content to be the world’s factory for biosimilar drugs. Alteogen is betting that delivery technology — the invisible infrastructure that determines how a drug reaches a patient — is where the next layer of value creation lives. If the Novartis deal matures as expected, it will have been right.